Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord blood-derived regulatory T cells (Second Xiangya Hospital)
- Development stage
- Unknown
- Lead developer
- The Second Xiangya Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord blood-derived regulatory T cells (Second Xiangya Hospital) is an investigational adoptive cell therapy being developed by the Second Xiangya Hospital of Central South University for the treatment of type 1 diabetes mellitus. The therapy involves the ex vivo expansion of allogeneic regulatory T cells (Tregs) isolated from umbilical cord blood. These cells are cultured and expanded using human recombinant IL-2 and rapamycin, and restimulated with CD3/CD28 dynabeads to ensure phenotypic stability and suppressive potency. The primary mechanism of action is the restoration of immune tolerance by suppressing the autoimmune destruction of pancreatic islet beta cells, thereby preserving residual insulin production. Clinical evaluation has progressed to Phase 1/2 trials in patients with autoimmune diabetes.
- Other names
- UCB-TregsEx-vivo expanded umbilical cord blood regulatory T cellsAllogeneic umbilical cord blood-derived regulatory T cells
Beyond the preview
Go deeper on umbilical cord blood-derived regulatory T cells (Second Xiangya Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord blood-derived regulatory T cells (Second Xiangya Hospital).